
Intercept Pharmaceuticals ICPT
Quarterly report 2023-Q3
added 11-06-2023
Intercept Pharmaceuticals Depreciation & Amortization 2011-2026 | ICPT
Annual Depreciation & Amortization Intercept Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 592 K | 2.81 M | 2.94 M | 3.66 M | 4.58 M | 4.6 M | 3.83 M | 1.69 M | 443 K | 106 K | 201 K | 411 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.6 M | 106 K | 2.16 M |
Quarterly Depreciation & Amortization Intercept Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 89 K | - | 491 K | - | 341 K | - | 2.43 M | - | 870 K | - | 2.28 M | 1.57 M | 764 K | - | 2.84 M | 1.92 M | 996 K | - | 3.55 M | 2.43 M | 1.29 M | - | 3.26 M | 1.87 M | 802 K | - | 2.19 M | 1.54 M | 684 K | - | 1.06 M | 646 K | 250 K | - | 210 K | 130 K | 61.7 K | - | 27 K | 30 K | 23 K | - | 178 K | 80 K | 74 K | - | 160 K | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.55 M | 23 K | 1.06 M |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ACADIA Pharmaceuticals
ACAD
|
920 K | $ 22.56 | 2.13 % | $ 3.74 B | ||
|
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
Akebia Therapeutics
AKBA
|
1.27 M | $ 1.43 | 3.62 % | $ 368 M | ||
|
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
55.7 M | $ 327.25 | 2.42 % | $ 42.9 B | ||
|
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
Autolus Therapeutics plc
AUTL
|
8.3 M | $ 1.49 | 9.56 % | $ 397 M | ||
|
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
31.6 M | $ 20.4 | -0.87 % | $ 954 M | ||
|
Aquestive Therapeutics
AQST
|
548 K | $ 4.18 | 1.21 % | $ 447 M | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
5.38 M | $ 2.66 | 3.5 % | $ 16.7 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
199 K | - | -2.5 % | $ 5.88 M | ||
|
Arcutis Biotherapeutics
ARQT
|
700 K | $ 24.61 | 5.76 % | $ 3.13 B | ||
|
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
66 K | - | - | $ 231 M | ||
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Cabaletta Bio
CABA
|
1.65 M | $ 3.09 | 0.65 % | $ 310 M | ||
|
CymaBay Therapeutics
CBAY
|
681 K | - | - | $ 3.45 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
Codiak BioSciences
CDAK
|
5.34 M | - | -55.98 % | $ 2.15 M | ||
|
Avid Bioservices
CDMO
|
11.1 M | - | - | $ 789 M | ||
|
Cidara Therapeutics
CDTX
|
154 K | - | - | $ 1.41 B | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Celldex Therapeutics
CLDX
|
3.38 M | $ 32.41 | 3.38 % | $ 2.15 B | ||
|
Celsion Corporation
CLSN
|
292 K | - | -6.63 % | $ 13.9 M | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Chimerix
CMRX
|
91 K | - | - | $ 756 M | ||
|
Concert Pharmaceuticals
CNCE
|
1.48 M | - | - | $ 401 M | ||
|
Akari Therapeutics, Plc
AKTX
|
14 K | $ 3.88 | 2.11 % | $ 261 B |